ONO 1301
Alternative Names: AP-50002; ONO 1301 - slow-release; ONO-1301-MS; ONO-AP-500-02; SR-ONOLatest Information Update: 28 Dec 2022
Price :
$50 *
At a glance
- Originator Ono Pharmaceutical
- Developer Ono Pharmaceutical; Osaka University
- Class Acetic acids; Anti-inflammatories; Antiplatelets; Pyridines; Small molecules
- Mechanism of Action Epoprostenol agonists; Prostaglandin agonists; Thromboxane synthase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Myocardial infarction; Myocardial ischaemia; Pulmonary fibrosis
- Discontinued Thrombosis
Most Recent Events
- 28 Dec 2022 No recent reports of development identified for preclinical development in Myocardial-ischaemia in Japan (Parenteral, Injection)
- 26 Dec 2022 No development reported - Preclinical for Myocardial infarction in Japan (PO)
- 13 Nov 2020 Preclinical development in Myocardial ischaemia is ongoing in Japan